Equities researchers at StockNews.com assumed coverage on shares of Global Cord Blood (NYSE:CO - Get Free Report) in a research report issued on Wednesday. The brokerage set a "strong-buy" rating on the medical research company's stock.
Global Cord Blood Stock Up 46.2 %
Shares of NYSE CO opened at $0.95 on Wednesday. Global Cord Blood has a twelve month low of $2.03 and a twelve month high of $5.50. The company's fifty day moving average is $0.92 and its 200-day moving average is $1.14. The stock has a market cap of $115.47 million, a price-to-earnings ratio of 1.48 and a beta of 0.16.
Global Cord Blood Company Profile
(
Get Free Report)
Global Cord Blood operates as a holding company, which engages in the provision of cord blood banking services. It provides cord blood processing and storage service. The company also offers cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services. The firm preserves cord blood units donated by the public and provides matching services on such donated units and deliver matching units to patients in need of transplants.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Global Cord Blood, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Global Cord Blood wasn't on the list.
While Global Cord Blood currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
